Canada · Delayed Price · Currency is CAD Canopy Growth Earnings Call Transcripts
Fiscal Year 2026
-
Q3 saw improved financial strength, record Canadian medical cannabis growth, and narrowing losses, supported by cost discipline and a $150M recapitalization. The MTL Cannabis acquisition is expected to boost margins and revenue, with positive Adjusted EBITDA targeted for fiscal 2027.
-
Q2 saw strong growth in Canadian adult-use and medical cannabis, margin expansion, and improved cash flow, while international sales declined due to supply issues. Cost-saving initiatives exceeded targets, and the balance sheet is significantly deleveraged. Outlook remains positive for core segments.
-
Q1 fiscal 2026 delivered 24% year-over-year cannabis revenue growth, led by strong Canada Medical and adult-use channels, while Storz & Bickel faced softer demand. Cost reductions and improved cash flow position the company for margin recovery and positive adjusted EBITDA in the second half.
Fiscal Year 2025
-
Shareholders approved all proposals, including director elections, auditor reappointment, share consolidation, and executive compensation. The board highlighted strong positioning for U.S. regulatory changes and emphasized risk factors in forward-looking statements.
-
The meeting was called to order virtually, but due to not meeting the required quorum, it was adjourned and rescheduled for October 10, 2025. Shareholders were informed of the new date and the meeting's virtual format.
-
Leadership executed major restructuring, cost reductions, and portfolio focus, driving improved margins and market share in Canadian medical cannabis, despite international and Storz & Bickel headwinds. Committed to positive adjusted EBITDA and free cash flow improvement in fiscal 2026.
-
Q3 FY2025 saw improved profitability with a narrowed Adjusted EBITDA loss and strong growth in medical cannabis and international markets, especially Europe. Integration of U.S. assets and cost reductions support a positive outlook for profitability and cash flow in FY2026.
-
Q2 FY2025 featured strong growth in Storz & Bickel and medical cannabis, offset by Canadian adult-use and Australian headwinds. Gross margin improved to 35%, and cost reductions continued, with positive Adjusted EBITDA targeted in coming quarters.
-
Achieved profitable adjusted EBITDA across all business units, with strong margin improvements and record growth in Canadian medical and German markets. Revenue declined year-over-year due to divestitures and supply constraints, but outlook remains positive with new product launches and expanded distribution expected to drive growth in the second half of fiscal 2025.
Fiscal Year 2024
-
The meeting covered financial results, board elections, auditor reappointment, and executive compensation, with all proposals approved. U.S. political developments and regulatory changes were discussed as key opportunities and risks. A brief Q&A addressed product preferences and industry outlook.